# Prognosis of HIV Patients Receiving Antiretroviral Therapy According to CD4 Counts: A Longterm Follow-up study in Yunnan, China

Li Ren<sup>1,2,3#</sup>, Juan Li<sup>4#</sup>, Shiyi Zhou<sup>5</sup>, Xueshan Xia<sup>6</sup>, Zhenrong Xie<sup>5</sup>, Pan Liu<sup>7</sup>, Yu Xu<sup>5</sup>, Yuan Qian<sup>8</sup>, Huifeng Zhang<sup>2</sup>, , Litang Ma<sup>8</sup>, Qiuwei Pan<sup>4</sup>, Kunhua Wang<sup>1,5\*</sup>

<sup>1</sup>Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, 650093, Yunnan Province, China;

<sup>2</sup>The First People's Hospital of Yunnan Province, Kunming, 650031, Yunnan Province, China;

<sup>3</sup>Medical faculty of Kunming University of Science and Technology, Kunming, 650093, Yunnan Province, China;

<sup>4</sup>Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, The Netherlands;

<sup>5</sup>Yunnan Institute of Digestive Disease, the First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan Province, China;

<sup>6</sup>Faculty of Life Science and Technology, Center for Molecular Medicine in Yunnan province, Kunming University of Science and Technology, Kunming, 650093, Yunnan Province, China;

<sup>7</sup>Yan'an Hospital of Kunming Chenggong hospital, Kunming, 650501, Yunnan Province, China;

<sup>8</sup>The First People's Hospital of Zhaotong City, Zhaotong, 657000, Yunnan Province, China.

## <sup>#</sup>These authors contributed equally.

#### \*Correspondence:

Kunhua Wang, Yunnan Institute of Digestive Disease, the First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Xichang Road 295, Yunnan Province, China.

Tel: (+86)871-6532 4888 Email: kunhuawangProf@163.com

Running title: Survival of antiretroviral treated HIV Patients

# Supplementary materials

Characteristics	Descriptive statistics		
Total			
no.	82		
Gender, no. (%)			
Male	58 (70.7)		
Female	24 (29.3)		
Marital status, no. (%)			
Unmarried	11 (13.4)		
Married	61 (74.4)		
Divorced	3 (3.7)		
Widowed	7 (8.5)		
Age at ART initiation, year			
Mean (SD)	47.6 (15.8)		
Median (IQR)	42.0 (34.3-60.0)		
WHO HIV Clinical Stage, no. (%)			
Stage I/II	35 (42.7)		
Stage III/IV	47 (57.3)		
CD4, cells/µl			
Mean (SD)	152.7 (128.9)		
Median (IQR)	129.0 (44.5-215.0)		
<50	21 (25.6)		
50-199	32 (39.0)		
≥200	22 (26.8)		
Transmission category, no. (%)			
Injecting drug users (IDU)	12 (14.6)		
Homosexual	0 (0)		
Heterosexual	53 (64.6)		
Others/unknown	17 (20.7)		

# Table S1. Baseline Characteristics of the Patients who Died at First6 Months of Follow-Up Period

ART indicates antiretroviral treatment

	rho	chisq	р
Gender			
Female	-	-	(Reference)
Male	-0.014	0.040	.841
Marital status			
Married	-	-	(Reference)
Unmarried	-0.071	1.073	.300
Divorced	0.107	2.25	.134
Widowed	0.066	0.991	.320
Age at ART initiation, year			
WHO HIV Clinical Stage			
Stage I/II	-	-	(Reference)
Stage III/IV	-0.081	1.536	.215
CD4, cells/µl			
≥200	-	-	(Reference)
50-199	-0.104	2.425	.119
<50	-0.150	5.029	.025
Transmission category			
Blood transfusion	-	-	(Reference)
Injecting drug users (IDU)	-0.031	0.192	.661
Homosexual	0.003	0.002	.957
Heterosexual	-0.039	0.296	.586
Mother-to-Child	-0.013	0.036	.850
Others/unknown	-0.022	0.093	.760
GLOBAL <sup>b</sup>	NA	19.958	.096

Table S2. Testing the Proportional Hazards Assumption of a Cox Regression Model Fit<sup>a</sup>

<sup>a</sup>Compuated by cox.zph() function in package of "survival" from R

<sup>b</sup>Indicates the global test

rho = Spearman's rank correlation coefficient



Figure S1. Cumulative morality from all-cause mortality for study population infected by human immunodeficiency virus (HIV) receiving antiretroviral therapy (ART) according to age (*p* <.0001). Corresponding numbers at risk at different time-points split by age categories have been indicated below the graph.



1980 (79%) patients underwent constant treatment

- 43 (2%) patients underwent drug switch due to drug interactions
- 288 (11%) patients underwent drug switch due to side effects
- 45 (2%) patients underwent drug switch due to firstline thearpy failure
- 161 (6%) patients underwent drug switch due to other reasons

Figure S2. The Pie Chart showing the percentage of patients who switched drugs during Antiretroviral Therapy.





B. Stacked bar chart



Figure S3: Plots presenting the values of baseline CD4 counts and 6-month CD4 counts for the patients who had survived 6 months after antiretroviral therapy. (A): histograms for continuous data of CD4 counts; (B): stacked bar chart for categorical data of CD4 counts: <50, 50-199, and ≥200 (unit: cells/µI).



**Figure S4: Plot of loss to follow up or not loss to follow up against survival time.** LFU = loss to follow up; NLFU = not loss to follow up.



Figure S5: Plot of scaled Schoenfeld residuals against transformed time for covariate CD4 count in Cox model fit. The upper solid line is a smoothing spline fit to the plot, with the broken lines representing a  $\pm$  2-standard-error band around the fit; and the bottom solid line is a horizontal line.

# Import data..... data1 <- read.csv ('HIV\_data.csv') # Split dataset into two time intervals: <=0.5 year; >0.5 year..... data2<-survival::survSplit(Surv(time,event)~.,data1,cut=c(0.5), episode = "tgroup", id="id") # Cox model..... # 1.Univariate analysis ## CD4 for two time intervals summmry(coxph(Surv(tstart,time,event)~CD4:strata(tgroup),data=data2) ## Other factors variables<-c('sex','marriage','transmission','WHO\_stage','age') lapply (variables, function(x)summary(coxph(Surv(time,event)~data2[,x],data=data2))) # 2.Multivariate analysis summary(coxph(Surv(tstart,Time\_m,Event)~CD4:strata(tgroup)+sex+marriage+transmission+WHO\_s tage+age, data=data2))

## Figure S6. R code for performing Cox proportional regression analyses